Acologix is a biology-based biopharmaceutical company focusing on the identification and development of novel therapeutics for major unmet medical needs. The Company name Acologix comes from the Greek word, acology, which means the science of remedies. The Company has six product candidates in its pipeline. Its lead compound, Dentonin (AC-100), completed a Phase I clinical trial in 2003 and is expected to enter a phase IIa study later in 2004. Acologix is now focused on the development of several additional product candidates which are planned to enter clinical trials in 2005. The current product candidates target the treatment of bone, teeth, kidney, vascular system and inflammatory diseases as well as metastatic cancer.


Date Type Amount Investors Valuation
02/14/06 Series C 29.8M AquaRIMCO, Diamond Capital, East Gate Private Equity Partners, JAIC America, SMBC Capital, Softbank, Toray Industries, UOB JAIC Venture Bio Investments, Nomura Research and Advisory Co., Tokio Marine and Fire Insurance Unknown


Sarbani Bhaduri (VP Medical Affairs)

Hatsushi Shimizu (Board Member)

Thomas Smart (VP Business Development)

Daniel Hoth (Board Member)

Yoshinari Kumagai (President/CEO)

View more details about all 10 people at Acologix